Open Access Articles- Top Results for Ranimustine


Systematic (IUPAC) name
methyl 6-({[(2-chloroethyl)(nitroso)amino]carbonyl}amino)-6-deoxy-α-D-glucopyranoside
Clinical data
AHFS/ International Drug Names
  • (Prescription only)
58994-96-0 7pxY
PubChem CID 71741
ChemSpider 64785
UNII RYH2T97J77 7pxY
Synonyms 1-(2-chloroethyl)-1-nitroso-3-([(2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-methoxyoxan-2-yl]methyl)urea
Chemical data
Formula C10H18ClN3O7
327.71 g/mol
 14pxY (what is this?)  (verify)

Ranimustine (INN, marketed under the tradename Cymerin; also known as MCNU) is a nitrosourea alkylating agent approved in Japan for the treatment of chronic myelogenous leukemia[1] and polycythemia vera.[2]

It has never been filed for FDA evaluation in the United States, where it is not marketed.


  1. ^ Kitajima K, Adachi T, Takahashi I et al. (November 1989). "[Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis]". Gan To Kagaku Ryoho (in Japanese) 16 (11): 3573–9. PMID 2817908. 
  2. ^ Nagai M, Tasaka T, Kamano H et al. (December 1988). "[Therapeutic effect of ranimustine (MCNU) on essential thrombocythemia and polycythemia vera]". Gan To Kagaku Ryoho (in Japanese) 15 (12): 3267–70. PMID 3196045. 

Lua error in package.lua at line 80: module 'Module:Buffer' not found.